{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T06:28:25Z","timestamp":1783405705693,"version":"3.54.6"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Clinical Research Institute at Rambam"},{"name":"Harvey and Gloria Kaylie Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Nephrologists play a key role in managing renal complications related to malignancy and its treatment. Although immunotherapies and oral small-molecule agents have revolutionized cancer care, severe adverse events may limit their use. We report a distinctive glomerular injury pattern associated with lenvatinib, an oral receptor tyrosine kinase inhibitor. Similar histopathologic features have been observed with bevacizumab and antivascular endothelial growth factor receptor 2 (VEGFR2) antibodies. This case includes extended clinical follow-up, kidney biopsy findings, and therapeutic modification, suggesting a possible association between VEGF\u2013VEGFR2 pathway inhibition and reversible nephrotoxicity.<\/jats:p>","DOI":"10.1093\/ckj\/sfag099","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:47:20Z","timestamp":1773924440000},"source":"Crossref","is-referenced-by-count":2,"title":["Lenvatinib-associated hyaline occlusive glomerular microangiopathy"],"prefix":"10.1093","volume":"19","author":[{"given":"Amir","family":"Daher","sequence":"first","affiliation":[{"name":"Rambam Health Care Campus, Haifa Department of Nephrology and Hypertension, ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Kenig-Kozlovsky","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Department of Nephrology and Hypertension, , Haifa ,","place":["Israel"]},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology, Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tchirkov","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Department of Nephrology and Hypertension, , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gai","family":"Milo","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Department of Nephrology and Hypertension, , Haifa ,","place":["Israel"]},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology , Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Ben-Itzhak","sequence":"additional","affiliation":[{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology , Haifa ,","place":["Israel"]},{"name":"Rambam Health Care Campus, Haifa Department of Pathology, ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7585-6952","authenticated-orcid":false,"given":"Suheir","family":"Assady","sequence":"additional","affiliation":[{"name":"Rambam Health Care Campus Department of Nephrology and Hypertension, , Haifa ,","place":["Israel"]},{"name":"The Ruth and Bruce Rappaport Faculty of Medicine, Technion\u2014Israel Institute of Technology , Haifa ,","place":["Israel"]},{"name":"Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,20]]},"reference":[{"key":"2026042108113627900_bib1","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"2026042108113627900_bib2","first-page":"e91970","article-title":"Lenvatinib-induced glomerular microangiopathy in a patient with poorly differentiated thyroid carcinoma: a long-term renal function change with biopsy findings","volume":"17","author":"Ishimura","year":"2025","journal-title":"Cureus"},{"key":"2026042108113627900_bib3","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/his.13716","article-title":"Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy","volume":"73","author":"Pfister","year":"2018","journal-title":"Histopathology"},{"key":"2026042108113627900_bib4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","article-title":"Inhibition of the VEGF signalling pathway and glomerular disorders","volume":"30","author":"Ollero","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026042108113627900_bib5","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"The Lancet"},{"key":"2026042108113627900_bib6","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.2169\/internalmedicine.8365-21","article-title":"Thrombotic microangiopathy, podocytopathy, and damage to the renal tubules with severe proteinuria and acute renal dysfunction induced by lenvatinib","volume":"61","author":"Nakashima","year":"2022","journal-title":"Intern Med"},{"key":"2026042108113627900_bib7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00428-021-03114-5","article-title":"Lenvatinib-related renal microangiopathy: a case series","volume":"480","author":"Delsante","year":"2022","journal-title":"Virchows Arch"},{"key":"2026042108113627900_bib8","first-page":"6927639","article-title":"A case of lenvatinib-induced focal segmental glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer","volume":"2018","author":"Fleming","year":"2018","journal-title":"Case Rep Oncol Med"},{"key":"2026042108113627900_bib9","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17425255.2018.1461839","article-title":"Lenvatinib-induced renal failure: two first-time case reports and review of literature","volume":"14","author":"Cavalieri","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026042108113627900_bib10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1172\/JCI86418","article-title":"VEGF regulates local inhibitory complement proteins in the eye and kidney","volume":"127","author":"Keir","year":"2017","journal-title":"J Clin Invest"},{"key":"2026042108113627900_bib11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/s41379-018-0186-4","article-title":"Bevacizumab-associated glomerular microangiopathy","volume":"32","author":"Person","year":"2019","journal-title":"Mod Pathol"},{"key":"2026042108113627900_bib12","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1007\/s10157-021-02090-z","article-title":"VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience","volume":"25","author":"Ozawa","year":"2021","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfag099\/67433925\/sfag099.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/4\/sfag099\/68113911\/sfag099.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/19\/4\/sfag099\/68113911\/sfag099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T12:11:44Z","timestamp":1776773504000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfag099\/8530515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfag099","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"value":"2048-8505","type":"print"},{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,20]]},"article-number":"sfag099"}}